威尔药业(603351) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥246,445,272.15, representing a decrease of 15.19% compared to the same period last year[3] - The net profit attributable to shareholders was ¥26,310,732.19, down by 4.43% year-on-year[3] - The basic earnings per share for the period was ¥0.20, reflecting a decline of 4.76% compared to the previous year[3] - Total operating revenue for Q1 2023 was CNY 246,445,272.15, a decrease of 15.2% compared to CNY 290,586,279.28 in Q1 2022[13] - Net profit for Q1 2023 was CNY 25,635,740.84, a decline of 4.2% from CNY 26,763,211.11 in Q1 2022[14] - The net profit attributable to the parent company for Q1 2023 was CNY 26,310,732.19, a decrease of 4.4% compared to CNY 27,529,731.11 in Q1 2022[15] - The total operating revenue from sales of goods and services in Q1 2023 was CNY 192,568,787.82, a decline of 9.4% from CNY 212,565,168.83 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,222,032,915.04, an increase of 3.92% from the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 2,222,032,915.04, an increase from CNY 2,138,160,094.23 at the end of 2022, marking a growth of 3.9%[12] - Total liabilities increased to CNY 701,845,128.22 from CNY 655,756,145.87 at the end of 2022, representing a rise of 7%[12] - Non-current assets totaled CNY 1,695,214,247.90, up from CNY 1,667,874,751.61 at the end of 2022, indicating a growth of 1.6%[11] Cash Flow - The net cash flow from operating activities was negative at -¥12,432,495.15, indicating a significant decline in cash generation[3] - The net cash flow from operating activities for Q1 2023 was negative at CNY -12,432,495.15, compared to a positive CNY 9,037,458.54 in Q1 2022[18] - The company incurred a total cash outflow from operating activities of CNY 207,996,715.51 in Q1 2023, slightly higher than CNY 205,447,864.92 in Q1 2022[18] - The net cash outflow from investing activities for Q1 2023 was CNY -31,422,829.04, compared to CNY -8,785,815.73 in Q1 2022[19] - The company reported cash inflows from financing activities of CNY 125,600,000.00 in Q1 2023, an increase from CNY 115,370,000.00 in Q1 2022[19] - The company reported a net cash inflow from financing activities of CNY 72,635,872.05 in Q1 2023, compared to CNY 66,972,377.01 in Q1 2022[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,087[6] - The top shareholder, Wu Renrong, holds 13.67% of the shares, with 10,890,000 shares pledged[7] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 214,807,670.05, down 16.6% from CNY 257,641,185.97 in Q1 2022[14] - The company reported R&D expenses of CNY 12,944,144.72 for Q1 2023, an increase of 19.3% compared to CNY 10,847,878.76 in Q1 2022[14] Inventory and Receivables - Cash and cash equivalents increased to CNY 128,322,164.94 as of March 31, 2023, compared to CNY 99,827,619.02 at the end of 2022, representing a growth of 28.5%[11] - Accounts receivable rose to CNY 152,574,670.50, slightly up from CNY 151,137,005.14 at the end of 2022, indicating a 1% increase[11] - Inventory increased to CNY 185,884,308.49, up from CNY 165,129,389.22 at the end of 2022, reflecting a growth of 12.5%[11] Borrowings - Long-term borrowings increased by 42.54%, attributed to new bank loans during the reporting period[5] Miscellaneous - The weighted average return on equity decreased by 0.21 percentage points to 1.76%[3] - The company did not report any net profit from the merged entity in the current or previous period[16]